Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability (Q29012696)

23 March 2017

1 reference

1 reference

Jun Ge

1

1 reference

23 March 2017

Ben-Xu Tan

2

1 reference

23 March 2017

Ye Chen

3

1 reference

23 March 2017

Li Yang

4

1 reference

23 March 2017

Xing-Chen Peng

5

1 reference

23 March 2017

Hong-Ze Li

6

1 reference

23 March 2017

Hong-Jun Lin

7

1 reference

23 March 2017

Yu Zhao

8

1 reference

23 March 2017

Meng Wei

9

1 reference

23 March 2017

Ke Cheng

10

1 reference

23 March 2017

Long-Hao Li

11

1 reference

23 March 2017

Hang Dong

12

1 reference

23 March 2017

Feng Gao

13

1 reference

23 March 2017

Jian-Ping He

14

1 reference

23 March 2017

Yang Wu

15

1 reference

23 March 2017

Meng Qiu

16

1 reference

23 March 2017

Ying-Lan Zhao

17

1 reference

23 March 2017

Jing-Mei Su

18

1 reference

23 March 2017

Jian-Mei Hou

19

1 reference

23 March 2017

Ji-Yan Liu

20

1 reference

23 March 2017

publication date

18 February 2011

1 reference

Journal of Molecular Medicine

23 March 2017

published in

1 reference

23 March 2017

volume

89

1 reference

23 March 2017

issue

6

1 reference

23 March 2017

page(s)

595-602

1 reference

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

23 March 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

Bortezomib and EGCG: no green tea for you?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

Green tea polyphenol epigallocatechin-3-gallate signaling pathway through 67-kDa laminin receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

Effects of green tea compounds on irinotecan metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

Effects of repeated green tea catechin administration on human cytochrome P450 activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

The combination of green tea and tamoxifen is effective against breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

Phase II study of sunitinib in patients with metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

A phase I study of sunitinib plus bevacizumab in advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

A detailed examination of boronic acid–diol complexation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0737-3

Protection against ultraviolet B radiation-induced photocarcinogenesis in hairless mice by green tea polyphenols

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21331509

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21331509

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00109-011-0737-3

1 reference